Skip to main content Accessibility help
  • Print publication year: 2014
  • Online publication date: October 2014

Chapter 17 - Parkinsonism

Related content

Powered by UNSILO


1. GibbWR, LeesAJ (1988). The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51: 745–752.
2. HughesAJ, DanielSE, et al. (2001). Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 57: 1497–1499.
3. MassanoJ, BhatiaKP (2012). Clinical approach to Parkinson’s disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med 2: a008870.
4. BrooksDJ (2010). Imaging approaches to Parkinson disease. J Nucl Med 51: 596–609.
5. PaulsonH, SternM (2004). Clinical manifestations of Parkinson’s disease. In WattsRL, KollerWC, eds. Movement Disorders: Neurologic Principles and Practive. 2nd edn. New York: McGraw-Hill, pp. 233–246.
6. Rodriguez-OrozMC, JahanshahiM, et al. (2009). Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol 8: 1128–1139.
7. BerardelliA, WenningGK, et al. (2013). EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol 20: 16–34.
8. HoehnMM, YahrMD (1967). Parkinsonism: onset, progression and mortality. Neurology 17: 427–442.
9. BergD, LangAE, et al. (2013). Changing the research criteria for the diagnosis of Parkinson’s disease: obstacles and opportunities. Lancet Neurol 12: 514–524.
10. PahwaR, LyonsKE (2010). Early diagnosis of Parkinson’s disease: recommendations from diagnostic clinical guidelines. Am J Manag Care 16 (suppl): S94–99.
11. SeppiK, PoeweW (2010). Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am 20: 29–55.
12. ZareiM, Ibarretxe-BilbaoN, et al. (2013). Cortical thinning is associated with disease stages and dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 84: 875–881.
13. CummingsJL, HenchcliffeC, et al. (2011). The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 134: 3146–3166.
14. GotoS, HiranoA, et al. (1989). Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson’s disease and striatonigral degeneration. Ann Neurol 26: 766–770.
15. WhoneAL, MooreRY, et al. (2003). Plasticity of the nigropallidal pathway in Parkinson’s disease. Ann Neurol 53: 206–213.
16. MarshallVL, PattersonJ, et al. (2006). Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun 27: 933–937.
17. EckertT, FeiginA, et al. (2007). Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging. Mov Disord 22: 167–173.
18. AntoniniA, SchwarzJ, et al. (1997). Long-term changes of striatal dopamine D2 receptors in patients with Parkinson’s disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 12: 33–38.
19. ShinotohH, InoueO, et al. (1993). Dopamine D1 receptors in Parkinson’s disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 56: 467–472.
20. EidelbergD, MoellerJR, et al. (1990). The metabolic anatomy of Parkinson’s disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 5: 203–213.
21. TangCC, PostonKL, et al. (2010). Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson’s disease. J Neurosci 30: 1049–1056.
22. BergD, GodauJ, et al. (2008). Transcranial sonography in movement disorders. Lancet Neurol 7: 1044–1055.
23. WalterU, BehnkeS, et al. (2007). Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol 33: 15–25.
24. BeckerG, SeufertJ, et al. (1995). Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial color-coded real-time sonography. Neurology 45: 182–184.
25. BusseK, HeilmannR, et al. (2012). Value of combined midbrain sonography, olfactory and motor function assessment in the differential diagnosis of early Parkinson’s disease. J Neurol Neurosurg Psychiatry 83: 441–447.
26. StocknerH, SchwingenschuhP, et al. (2012). Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson’s disease?Mov Disord 27: 1182–1185.
27. CourbonF, Brefel-CourbonC, et al. (2003). Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord 18: 890–897.
28. NagayamaH, HamamotoM, et al. (2005). Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 76: 249–251.
29. GengDY, LiYX, et al. (2006). Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson’s disease. Neurosurgery 58: 256–262.
30. LehericyS, SharmanMA, et al. (2012). Magnetic resonance imaging of the substantia nigra in Parkinson’s disease. Mov Disord 27: 822–830.
31. StoesslAJ, MartinWW, et al. (2011). Advances in imaging in Parkinson’s disease. Lancet Neurol 10: 987–1001.
32. VaillancourtDE, SprakerMB, et al. (2009). High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 72: 1378–1384.
33. PeranP, CherubiniA, et al. (2010). Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature. Brain 133: 3423–3433.
34. SasakiM, ShibataE, et al. (2006). Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson’s disease. Neuroreport 17: 1215–1218.
35. SchwarzST, RittmanT, et al. (2011). T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson’s disease. Mov Disord 26: 1633–1638.
36. OhtsukaC, SasakiM, et al. (2013). Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson’s disease using neuromelanin-sensitive MR imaging. Neurosci Lett 541: 93–98.
37. MartinWR, WielerM, et al. (2008). Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70: 1411–1417.
38. OrdidgeRJ, GorellJM, et al. (1994). Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 32: 335–341.
39. ChoZH, OhSH, et al. (2011). Direct visualization of Parkinson’s disease by in vivo human brain imaging using 7.0 T magnetic resonance imaging. Mov Disord 26: 713–718.
40. KwonDH, KimJM, et al. (2012). Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 71: 267–277.
41. KhanNL, ScherflerC, et al. (2005). Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single Parkin mutation. Neurology 64: 134–136.
42. PicciniP, MorrishPK, et al. (1997). Dopaminergic function in familial Parkinson’s disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol 41: 222–229.
43. PonsenMM, StoffersD, et al. (2004). Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56: 173–181.
44. EisensehrI, LinkeR, et al. (2000). Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson’s disease and controls. Brain 123: 1155–1160.
45. IranzoA, LomenaF, et al. (2010). Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol 9: 1070–1077.
46. WalterU, KleinC, et al. (2004). Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 19: 1445–1449.
47. SommerU, HummelT, et al. (2004). Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19: 1196–1202.
48. SvenningssonP, WestmanE, et al. (2012). Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol 11: 697–707.
49. EvansJR, MasonSL, et al. (2011). The natural history of treated Parkinson’s disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 82: 1112–1118.
50. KehagiaAA, BarkerRA, et al. (2010). Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol 9: 1200–1213.
51. Liepelt-ScarfoneI, GraberS, et al. (2012). Cognitive profiles in Parkinson’s disease and their relation to dementia: a data-driven approach. Int J Alzheimers Dis : 910757.
52. LitvanI, GoldmanJG, et al. (2012). Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27: 349–356.
53. ChristopherL, StrafellaAP (2013). Neuroimaging of brain changes associated with cognitive impairment in Parkinson’s disease. J Neuropsychol 7: 225–240.
54. EmreM, AarslandD, et al. (2007). Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22: 1689–1707.
55. O’BrienJT, CollobyS, et al. (2004). Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61: 919–925.
56. RinneJO, PortinR, et al. (2000). Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol 57: 470–475.
57. CollobySJ, WilliamsED, et al. (2005). Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson’s disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 32: 1176–1185.
58. KuhlDE, MinoshimaS, et al. (1996). In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol 40: 399–410.
59. HilkerR, ThomasAV, et al. (2005). Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65: 1716–1722.
60. PappataS, SantangeloG, et al. (2011). Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 77: 1357–1362.
61. BohnenNI, KoeppeRA, et al. (2011). Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 52: 848–855.
62. HuangC, MattisP, et al. (2007). Metabolic brain networks associated with cognitive function in Parkinson’s disease. Neuroimage 34: 714–723.
63. HiranoS, ShinotohH, et al. (2012). Functional brain imaging of cognitive dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry 83: 963–969.
64. ComptaY, ParkkinenL, et al. (2011). Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important?Brain 134: 1493–1505.
65. BrooksDJ (2009). Imaging amyloid in Parkinson’s disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord 24 (suppl 2): S742–747.
66. GompertsSN, LocascioJJ, et al. (2013). Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 80: 85–91.
67. PetrouM, BohnenNI, et al. (2012). A beta-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 79: 1161–1167.
68. BurtonEJ, McKeithIG, et al. (2004). Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies and controls. Brain 127: 791–800.
69. ApostolovaLG, BeyerM, et al. (2010). Hippocampal, caudate, and ventricular changes in Parkinson’s disease with and without dementia. Mov Disord 25: 687–695.
70. Nagano-SaitoA, WashimiY, et al. (2005). Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 64: 224–229.
71. SummerfieldC, JunqueC, et al. (2005). Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 62: 281–285.
72. TamCW, BurtonEJ, et al. (2005). Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 64: 861–865.
73. BeyerMK, JanvinCC, et al. (2007). A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 78: 254–259.
74. AlmeidaOP, BurtonEJ, et al. (2003). MRI study of caudate nucleus volume in Parkinson’s disease with and without dementia with Lewy bodies and Alzheimer’s disease. Dement Geriatr Cogn Disord 16: 57–63.
75. CamicioliR, SabinoJ, et al. (2011). Ventricular dilatation and brain atrophy in patients with Parkinson’s disease with incipient dementia. Mov Disord 26: 1443–1450.
76. LeeJE, ParkHJ, et al. (2010). Neuroanatomic basis of amnestic MCI differs in patients with and without Parkinson disease. Neurology 75: 2009–2016.
77. SongSK, LeeJE, et al. (2011). The pattern of cortical atrophy in patients with Parkinson’s disease according to cognitive status. Mov Disord 26: 289–296.
78. MelzerTR, WattsR, et al. (2012). Grey matter atrophy in cognitively impaired Parkinson’s disease. J Neurol Neurosurg Psychiatry 83: 188–194.
79. DuncanGW, FirbankMJ, et al. (2013). Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson’s disease?Mov Disord 28: 425–438.
80. Karagulle KendiAT, LehericyS, et al. (2008). Altered diffusion in the frontal lobe in Parkinson disease. AJNR 29: 501–505.
81. MatsuiH, NishinakaK, et al. (2007). Wisconsin Card Sorting Test in Parkinson’s disease: diffusion tensor imaging. Acta Neurol Scand 116: 108–112.
82. RaeCL, CorreiaMM, et al. (2012). White matter pathology in Parkinson’s disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage 62: 1675–1684.
83. BertrandJA, BedettiC, et al. (2010). Color discrimination deficits in Parkinson’s disease are related to cognitive impairment and white-matter alterations. Mov Disord 27: 1781–1788.
84. AgostaF, CanuE, et al. (2013).The topography of brain damage at different stages of Parkinson’s disease. Hum Brain Mapp 34: 2798–2807.
85. HattoriT, OrimoS, et al. (2012). Cognitive status correlates with white matter alteration in Parkinson’s disease. Hum Brain Mapp 33: 727–739.
86. DengB, ZhangY, et al. (2013). Diffusion tensor imaging reveals white matter changes associated with cognitive status in patients with Parkinson’s disease. Am J Alzheimers Dis Other Demen 28: 154–164.
87. AgostaF, CanuE, et al. (2013). Mild cognitive impairment in PD is associated with a distributed pattern of brain white matter damage. Hum Brain Mapp: Epub ahead of print, doi: 10.1002/hbm.22302.
88. McKeithI, MintzerJ, et al. (2004). Dementia with Lewy bodies. Lancet Neurol 3: 19–28.
89. McKeithIG, DicksonDW, et al. (2005). Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863–1872.
90. McKeithI, O’BrienJ, et al. (2007). Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6: 305–313.
91. O’BrienJT, McKeithIG, et al. (2009). Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 194: 34–39.
92. WalkerZ, JarosE, et al. (2007). Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 78: 1176–1181.
93. KleinJC, EggersC, et al. (2010). Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 74: 885–892.
94. IshiiK, SomaT, et al. (2007). Comparison of regional brain volume and glucose metabolism between patients with mild dementia with Lewy bodies and those with mild Alzheimer’s disease. J Nucl Med 48: 704–711.
95. MinoshimaS, FosterNL, et al. (2001). Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 50: 358–365.
96. MosconiL, TsuiWH, et al. (2008). Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med 49: 390–398.
97. IshiiK, ImamuraT, et al. (1998). Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology 51: 125–130.
98. TeuneLK, BartelsAL, et al. (2010). Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 25: 2395–2404.
99. HiguchiM, TashiroM, et al. (2000). Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 162: 247–256.
100. EdisonP, RoweCC, et al. (2008). Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79: 1331–1338.
101. VillemagneVL, OngK, et al. (2011). Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 52: 1210–1217.
102. BeyerMK, LarsenJP, et al. (2007). Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 69: 747–754.
103. BurtonEJ, BarberR, et al. (2009). Medial temporal lobe atrophy on MRI differentiates Alzheimer’s disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 132: 195–203.
104. BurtonEJ, KarasG, et al. (2002). Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 17: 618–630.
105. WhitwellJL, WeigandSD, et al. (2007). Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer’s disease. Brain 130: 708–719.
106. BallmaierM, O’BrienJT, et al. (2004). Comparing gray matter loss profiles between dementia with Lewy bodies and Alzheimer’s disease using cortical pattern matching: diagnosis and gender effects. Neuroimage 23: 325–335.
107. MiddelkoopHA, van der FlierWM, et al. (2001). Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology 57: 2117–2120.
108. CousinsDA, BurtonEJ, et al. (2003). Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer’s disease: an MRI study. Neurology 61: 1191–1195.
109. BarberR, McKeithI, et al. (2002). Volumetric MRI study of the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. J Neurol Neurosurg Psychiatry 72: 406–407.